Rotavirus vaccines for the developing world

Current Opinion in Infectious Diseases

Volumn 22, Issue 5, 2009, Pages 483-489

  Oryan, Miguel L ^a   Hermosilla, German ^a   Osorio, Gonzalo ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Diarrhea; Gastroenteritis; Rotavirus; Serotypes; Vaccines

Indexed keywords

PLACEBO; PROTEIN VP4; PROTEIN VP7; ROTAVIRUS VACCINE;

CHILD; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIARRHEA; DRUG COST; DRUG EFFICACY; FUNDING; GOVERNMENT; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; INTUSSUSCEPTION; MULTICENTER STUDY; NONHUMAN; PREVALENCE; REVIEW; ROTAVIRUS; SEROTYPE; VACCINATION; VIRAL GASTROENTERITIS; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INFECTION;

DEVELOPING COUNTRIES; HOST-PATHOGEN INTERACTIONS; HUMANS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 70249084570     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833040a9     Document Type: Review

References (48)

1. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983; 309:72-76.
2. Velasquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-1028.
3. Fischer T, Valentiner-Branth P, Steinsland H, et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, West Africa. J Infect Dis 2002; 186:593-597.
4. Ball JM, Tian P, Zeng CQ, etal. Age-dependent diarrhea induced by arotaviral nonstructural glycoprotein. Science 1996; 272:101-104.
5. Lorrot M, Vasseur M. How do the rotavirus NSP4 and bacterial enterotoxins lead differently to diarrhea? Virol J 2007; 21:4-31.
6. Seo NS, Zeng CQ, Hyser JM, et al. Integrins alpha1beta1 and alpha2beta1 are receptors for the rotavirus enterotoxin. Proc Natl Acad Sci USA 2008; 105:8811-8818.
7. Rajasekaran D, Sastri NP, Marathahalli JR, et al. The flexible C terminus of the rotavirus nonstructural protein NSP4 is an important determinant of its biological properties. J Gen Virol 2008; 89:1485-1496.
8. Hou Z, Huang Y, Huan Y, et al. Anti-NSP4 antibody can block rotavirus induced diarrhea in mice. J Pediatr Gastroenterol Nutr 2008; 46:376-385.
9. Kirkwood CD, Boniface K, Richardson S, etal. Nonstructural protein NSP2 induces heterotypic antibody responses during primary rotavirus infection and reinfection in children. J Med Virol 2008; 80:1090-1098.
10. Yuan L, Wen K, Azevedo MS, et al. Virus-specific intestinal IFN-gamma producing T cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs. Vaccine 2008; 26:3322-3331.
11. Blutt SE, Warfield KL, Estes MK, Conner ME. Differential requirements for T cells in virus like particle- and rotavirus-induced protective immunity. J Virol 2008; 82:3135-3138.
12. Kim B, Feng N, Narvaez CF, et al. The influence of CD4+ CD25+ Foxp3+ regulatory T cells on the immune response to rotavirus infection. Vaccine 2008; 26:5601-5611.
13. Centers for disease control and prevention (CDC). Rotavirus surveillance: worldwide, 2001-2008. Morb Mortal Wkly Rep 2008; 57:1255-1257.
14. Grassi T, Bagordo F, Idolo A, etal. Rotavirus detection in environmental water samples by tangential flow ultrafiltration and RT-nested PCR. Environ Monit Assess 2009 [Epub ahead of print]. doi:10.1007/s10661-009-0885-x.
15. Espinosa AC, Mazari-Hiriart M, Espinosa R, et al. Infectivity and genome persistence of rotavirus and astrovirus in groundwater and surface water. Water Res 2008; 42:2618-2628.
16. McDonald SM, Aguayo D, Gonzalez-Nilo FD, Patton JT. Shared and group-specific features of the rotavirus RNA polymerase reveal potential deter minants of gene reassortment restriction. J Virol 2009; 83:6135-6148.
17. Mukherjee A, Dutta D, Ghosh S, et al. Full genomic analysis of a human group A rotavirus G9P[6] strain from Eastern India provides evidence for porcine-to-human interspecies transmission. Arch Virol 2009; 154:733-746.
18. Esona MD, Geyer A, Page N, et al. Genomic characterization of human rotavirus G8 strains from the African rotavirus network: relationship to animal rotaviruses. J Med Virol 2009; 81:937-951.
19. Freeman MM, Kerin T, Hull J, et al. Phylogenetic analysis of novel G12 rotaviruses in the United States: a molecular search for the origin of a new strain. J Med Virol 2009; 81:736-746.
20. Page NA, de Beer MC, Seheri LM, et al. The detection and molecular characterization of human G12 genotypes in South Africa. J Med Virol 2009; 81:106-113.
21. Cunliffe NA, Ngwira BM, Dove W, et al. Serotype G12 rotaviruses, Lilongwe, Malawi. Emerg Infect Dis 2009; 15:87-90.
22. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
23. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33. (Pubitemid 43048948)
24. O?Ryan M, Matson DO. New rotavirus vaccines: renewed optimism. J Pediatr 2006; 149:448-451.
25. O?Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev Vaccines 2007; 6:11-19.
26. Matson DO. The pentavalent rotavirus vaccine, RotaTeq. Semin Pediatr Infect Dis 2006; 17:195-199.
27. Linhares A, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomized, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-1189.
28. Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev 2008; 21:198-208.
29. Fu C, Wang M, Liang J, et al. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study. Vaccine 2007; 25:8756-8761.
30. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-2251.
31. Neuzil K, Madhi S, Cunliffe N. Rix4414 is protective against severe RVGE caused by diverse rotavirus serotypes during the first year of life in African infants. 26th Meeting of the European Society of Pediatric Infectious Diseases. Brussels, Belgium, June 9-13, 2009; abstract 820.
32. Cunliffe N, Kirsten M, Madhi S, et al. Efficacy of human rotavirus vaccines RIX4414 in Africa during the first year of life. 26th Meeting of the European Society of Pediatric Infectious Diseases. Brussels, Belgium, June 9-13, 2009; abstract 572.
33. Dennehy P, Bertrand H, Silas P, et al. Co administration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the Unites States. Pediatrics 2008; 122:e1062-e1066.
34. Ciarlet M, Sani-Grosso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008; 27:874-880.
35. Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influen zae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J 2009; 28:177-181.
36. Steele AD, De Vos B, Tumboc J, et al. Co-administration study in South ;African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2008 [Epub ahead of print].
37. Van der Wielen M, Van Damme P. Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial. Eur J Clin Microbiol Infect Dis 2008; 27:495-501.
38. Omeñaca F, Sarlangue J, Wysocki J, et al., Immunogenicity of a rotavirus vaccine (RIX4414) in European preterm infants with different gestational age. 26th Meeting of the European Society of Pediatric Infectious Diseases. Brussels, Belgium, June 9-13, 2009; abstract 645.
39. Phua K, Lim F, Lau Y, et al. Human rotavirus vaccine RIX4414 is highly efficacious in Asian infants during the third year of life. 26th Meeting of the European Society of Pediatric Infectious Diseases. Brussels, Belgium, June 9-13, 2009; abstract 572.
40. Carvalho-Costa FA, Araújo IT, Santos de Assis RM, et al. Rotavirus genotype distribution after vaccine introduction, Rio de Janeiro, Brazil. Emerg Infect Dis 2009; 15:95-97.
41. Antunes H, Afonso A, Iturriza M, et al. G2P[4] the most prevalent rotavirus genotype in 2007 winter season in an European nonvaccinated population. J Clin Virol 2009; 45:76-78.
42. Narang A, Bose A, Pandit AN, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin 2009; 5:414-419.
43. Rheingans RD, Constenla D, Antil L, et al. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21:205-216. (Pubitemid 47147596)
44. Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008; 8:103-115.
45. KimSY, Goldie SJ, Salomon JA. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 2009; 9:29-40.
46. Centers for Disease Control and Prevention (CDC). Delayed onset and •• diminished magnitude of rotavirus activity: United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57:697-700.
47. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts 2009: conclusion and recommendations. Weekly Epidemiological Record 2009; 84: 213-236.
48. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Virus particles in epithelial cells of duodenal mucosa from children with acute nonbacterial gastroenteritis. Lancet 1973; ii:1281-1283.